Background: Many patients with moderate to severe Crohn’s disease (CD) are treated with infliximab (IFX). As most of these patients experience a long-lasting therapy, the outcome and withdrawal of IFX treatment are important clinical questions. Methods: In this retrospective study, we analyzed the treatment outcome in moderate to severe CD patients with a steroid-dependent/refractory disease course started on IFX. Withdrawal of IFX was evaluated in patients with deep remission defined as clinical (Harvey-Bradshaw Index ≤4), biochemical (fecal calprotectin [FC] ≤150 μg/g stool) over a period of 2 years, and endoscopic and histological remission before discontinuation of IFX. Results: After induction with IFX, clinical remission was observed in 45/109 patients (41.3%) and clinical response in 61/109 patients (56.0%). Only 8/109 patients (7.3%) achieved deep remission and therefore could be discontinued from IFX therapy. In 4 of these patients (50%), relapse was observed after discontinuation of IFX treatment. FC decreased in these 8 patients in deep remission from 652 ± 168 μg/g stool (mean ± SE) at baseline to 24.9 ± 8.1 μg/g stool at 14 weeks. When compared to patients in deep remission, FC had decreased significantly less at 14 weeks in patients in clinical remission after induction with IFX (n = 31; 154 ± 55 μg/g stool; p = 0.01), in patients with clinical response after induction achieving clinical remission during the maintenance phase (n = 11; 352 ± 67 μg/g stool; p = 0.004), or in patients with chronic active disease course on maintenance therapy (n = 50; 645 ± 93 μg/g stool; p < 0.001). Conclusion: A low discontinuation rate was observed for steroid-dependent/refractory moderate to severe CD patients with IFX treatment. As FC showed a more or less pronounced decrease depending on the response to the IFX treatment, monitoring of FC may become a noninvasive tool for tailoring biological therapy in CD patients.

Keywords:
Crohn’s disease, Fecal calprotectin, Infliximab, Relapse, Remission
1.
Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al: The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010; 4: 28–62.
2.
D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, et al: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199–212; quiz 213.
3.
Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, et al: When do we dare to stop biological or immunomodulatory therapy for Crohn’s disease? Results of a multidisciplinary European expert panel. J Crohns Colitis 2013; 7: 820–826.
4.
Clarke K, Regueiro M: Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012; 18: 174–179.
5.
Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, et al: Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63–70.e5; quiz e31.
6.
Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Ostergaard Thomsen O, Seidelin JB: Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012; 47: 518–527.
7.
Poullis A, Foster R, Mendall MA, Fagerhol MK: Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003; 18: 756–762.
8.
Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al: A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000; 47: 506–513.
9.
Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al: Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894–1899.
10.
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15–22.
11.
Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, et al: Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000; 95: 2831–2837.
12.
Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F: Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32–39.
13.
Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M: Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40–46.
14.
Vieira A, Fang CB, Rolim EG, Klug WA, Steinwurz F, Rossini LG, et al: Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009; 2: 221.
15.
D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al: Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218–2224.
16.
Sipponen T, Savilahti E, Karkkainen P, Kolho KL, Nuutinen H, Turunen U, et al: Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis 2008; 14: 1392–1398.
17.
Molander P, af Bjorkesten CG, Mustonen H, Haapamaki J, Vauhkonen M, Kolho KL, et al: Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis 2012; 18: 2011–2017.
18.
Scaioli E, Cardamone C, Scagliarini M, Zagari RM, Bazzoli F, Belluzzi A: Can fecal calprotectin better stratify Crohn’s disease activity index? Ann Gastroenterol 2015; 28: 247–252.
19.
Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, et al: Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scand J Gastroenterol 2016; 51: 196–202.
20.
Danese S, Colombel JF, Reinisch W, Rutgeerts PJ: Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011; 33: 857–869.
21.
Louis E, Belaiche J, Reenaers C: Anti-TNF and Crohn’s disease: when should we stop? Curr Drug Targets 2010; 11: 148–151.
22.
Gisbert JP, Marin AC, McNicholl AG, Cha­parro M: Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015; 41: 613–623.
23.
Farkas K, Lakatos PL, Szucs M, Pallagi-Kunstar E, Balint A, Nagy F, et al: Frequency and prognostic role of mucosal healing in patients with Crohn’s disease and ulcerative colitis after one-year of biological therapy. World J Gastroenterol 2014; 20: 2995–3001.
24.
Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, et al: Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. J Crohns Colitis 2013; 7: 730–735.
25.
Hlavaty T, Krajcovicova A, Letkovsky J, Sturdik I, Koller T, Toth J, et al: Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy. Bratisl Lek Listy 2016; 117: 205–211.
26.
Molander P, Farkkila M, Salminen K, Kemppainen H, Blomster T, Koskela R, et al: Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis 2014; 20: 1021–1028.
27.
Casanova MJ, Chaparro M, Garcia-Sanchez V, Nantes O, Leo E, Rojas-Feria M, et al: Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study. Am J Gastroenterol 2017; 112: 120–131.
28.
Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B, et al: Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther 2015; 42: 356–364.
29.
Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al: Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005; 54: 364–368.
30.
D’Inca R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, et al: Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008; 103: 2007–2014.
31.
Gisbert JP, Bermejo F, Perez-Calle JL, Taxonera C, Vera I, McNicholl AG, et al: Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190–1198.
32.
Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, et al: Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2008; 6: 1218–1224.
33.
Molander P, Farkkila M, Ristimaki A, Salmi­nen K, Kemppainen H, Blomster T, et al: Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis 2015; 9: 33–40.
34.
Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, Gisbert JP, Gallardo-Valverde JM, Gonzalez-Galilea A, et al: Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis 2010; 4: 144–152.
35.
Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, et al: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther 2014; 40: 1313–1323.
36.
Osterman MT: Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol 2013; 47: 212–221.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.